Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

PDL BIOPHARMA, INC. Form 8-K January 22, 2010

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 21, 2010

# PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756

(Commission File Number)

Delaware (State or Other Jurisdiction 94-3023969 (I.R.S. Employer

# Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

of Incorporation) Identification No.)

#### 932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

#### Item 8.01 Other Events.

On January 21, 2010, PDL BioPharma, Inc. issued a press release regarding the allocation between dividend income and return of capital for federal income tax purposes for dividends paid in 2009. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

No.	Description
99.1	Press Release, Dated January 21, 2010 Regarding 2009 Dividend Payments

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ Christine Larson

Christine Larson Vice President and Chief Financial Officer

Dated: January 22, 2010

# EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, Dated January 21, 2010 Regarding 2009 Dividend Payments